MedTrace Logo

Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy

NCT03366571 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2021-04-14

No results posted yet for this study

Summary

Patients who have completed 3 years follow-up of the past Beijing Science and Technology Commission Research will receive another 7-years anti-viral therapy. Patients will be assessed at baseline and every six months for blood cell count, liver function test, HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan. CT or MRI and endoscopy will be performed at baseline and 7 years. At the end of the study, the cumulative rate of clinical hepatic hard endpoint will be calculated.

Conditions

Interventions

DRUG

Nucleos(t)ide Analogues

Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Peking University People's Hospital

    collaborator OTHER

  • Beijing YouAn Hospital

    collaborator OTHER

  • Beijing Ditan Hospital

    collaborator OTHER

  • Beijing Friendship Hospital

    lead OTHER

Principal Investigators

  • Dong J Jia, Doctor · Beijing Friendship Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03366571 on ClinicalTrials.gov